84 related articles for article (PubMed ID: 10199156)
1. [Sulfonylurea drug--a new sulfonylurea drug for type 2 diabetes].
Toyota T
Nihon Rinsho; 1999 Mar; 57(3):695-701. PubMed ID: 10199156
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
Johnson JL; Wolf SL; Kabadi UM
Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
[TBL] [Abstract][Full Text] [Related]
3. Hypoglycemic and hypotriglyceridemic effects of tolbutamide in triphenyltin chloride-induced diabetic rabbits.
Watanabe M; Watanabe K; Matsui H
Vet Hum Toxicol; 2002 Jun; 44(3):140-4. PubMed ID: 12046964
[TBL] [Abstract][Full Text] [Related]
4. Oral hypoglycemic agents in type II diabetes mellitus.
Lubbos H; Miller JL; Rose LI
Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
[TBL] [Abstract][Full Text] [Related]
5. [Glimepiride in daily practice].
Jasik M
Przegl Lek; 2003; 60(6):409-12. PubMed ID: 14974179
[TBL] [Abstract][Full Text] [Related]
6. Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine.
Riddle MC
Horm Metab Res; 1996 Sep; 28(9):430-3. PubMed ID: 8911978
[TBL] [Abstract][Full Text] [Related]
7. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 1998 Oct; 32(10):1044-52. PubMed ID: 9793597
[TBL] [Abstract][Full Text] [Related]
8. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
Massi-Benedetti M; Herz M; Pfeiffer C
Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
10. The role of glimepiride in the effective management of Type 2 diabetes.
Davis SN
J Diabetes Complications; 2004; 18(6):367-76. PubMed ID: 15531188
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance determines efficacy of glimepiride in Type 2 diabetic patients not well controlled by diet alone.
Shimizu H; Monden T; Nagai T; Shoda Y; Sato T; Yamada M; Mori M
Diabet Med; 2005 Feb; 22(2):225-6. PubMed ID: 15660744
[No Abstract] [Full Text] [Related]
12. [Delayed sulfonylurea resistance in non-insulin-dependent diabetes mellitus].
Farkas K; Jermendy G; Somogyi A
Orv Hetil; 1997 Nov; 138(48):3031-5. PubMed ID: 9441264
[TBL] [Abstract][Full Text] [Related]
13. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
14. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
15. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea.
Kabadi UM; Kabadi MU
J Fam Pract; 1991 Oct; 33(4):349-53. PubMed ID: 1919450
[TBL] [Abstract][Full Text] [Related]
16. [Combined insulin and sulfonylurea treatment in diabetes mellitus].
Ravina A; Minuhin O
Harefuah; 1986 Jan; 110(1):11-4. PubMed ID: 3514394
[No Abstract] [Full Text] [Related]
17. [Treatment of diabetic nephropathy--control of blood glucose].
Nishishita S; Shikata K; Makino H
Nihon Rinsho; 2005 Jun; 63 Suppl 6():384-8. PubMed ID: 15999739
[No Abstract] [Full Text] [Related]
18. The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel.
Chistiakov DA; Potapov VA; Smetanina SA; Bel'chikova LN; Suplotova LA; Nosikov VV
Acta Diabetol; 2011 Sep; 48(3):227-35. PubMed ID: 21611789
[TBL] [Abstract][Full Text] [Related]
19. Clinical review of glimepiride.
McCall AL
Expert Opin Pharmacother; 2001 Apr; 2(4):699-713. PubMed ID: 11336617
[TBL] [Abstract][Full Text] [Related]
20. [Glimepiride (Amaryl): a review of its pharmacological and clinical profile].
Bando K; Yamada Y
Nihon Yakurigaku Zasshi; 2001 Jul; 118(1):59-67. PubMed ID: 11496829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
